David Roblin, president of research and development at Summit Therapeutics Plc, has been appointed chair of a new scientific advisory board at Destiny Pharma Plc to help guide development of the company’s anti-microbial drug portfolio. Dr Roblin was a non-executive director at Destiny from 2011 to May 2017. He was previously chief operating officer at the Francis Crick Institute in London, UK.
Also joining the advisory board are Richard Proctor, professor emeritus at the University of Wisconsin School of Medicine and Public Health in Madison, US; Vance Garrison Fowler Jr, professor in the Departments of Medicine and Molecular Genetics & Microbiology at the Duke University Medical Center, US; Leonard Alan Mermel, formerly of the US Department of Health and Human Services and Glenn JR Whitman, professor of surgery at the Johns Hopkins School of Medicine, US.
Destiny Pharma announced the appointments on 30 May 2018.
Copyright 2018 Evernow Publishing Ltd